» Articles » PMID: 6427998

Adoptive Immunization Against an Established Tumor with Cytolytic Versus Memory T Cells. Immediate Versus Delayed Onset of Regression

Overview
Journal Transplantation
Specialty General Surgery
Date 1984 Jun 1
PMID 6427998
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Intradermal injection of an admixture of P815 tumor cells and Corynebacterium parvum results in the emergence of a tumor that grows progressively for 9-10 days and then undergoes complete regression. Tumor regression is preceded by a cytolytic T cell response in the spleen that peaks on day 10 and then undergoes progressive decay until days 15-16 when cytolytic T cells can no longer be detected. Passive transfer of 10-day or 30-day spleen cells to T-cell-deficient recipients bearing a 4-day tumor resulted in complete tumor regression. However, whereas passively transferred 10 day spleen cells caused the onset of tumor regression within 2 days, passively transferred 30-day spleen cells did not cause tumor regression until after a 6-8-day delay. Again, the antitumor function of 10-day spleen cells could be eliminated by treatment with cyclophosphamide and vinblastine sulfate, whereas 30 day spleen cells were resistant to both agents. These results indicate that 10-day spleen cells are physiologically different from 30-day spleen cells. The results are consistent with the interpretation that passively transferred 10-day spleen cells cause rapid onset of tumor regression because they are cytolytic T cells and have an immediate capacity to destroy the tumor. In contrast, 30-day spleen cells are helper or memory T cells with no capacity at the time of transfer to destroy the tumor.

Citing Articles

Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells.

Tanaka H, Matsushima H, Mizumoto N, Takashima A Cancer Res. 2009; 69(17):6978-86.

PMID: 19706756 PMC: 2769260. DOI: 10.1158/0008-5472.CAN-09-1101.


Effect of murine interferon alpha/beta on tumour-induced suppressor function.

Sahasrabudhe D, Dusel J Cancer Immunol Immunother. 1994; 39(6):360-6.

PMID: 8001023 PMC: 11038840. DOI: 10.1007/BF01534422.


The therapeutic significance of concomitant antitumor immunity. I. LY-1-2+ T cells from mice with a progressive tumor can cause regression of an established tumor in gamma-irradiated recipients.

NORTH R Cancer Immunol Immunother. 1984; 18(2):69-74.

PMID: 6334549 PMC: 11039104. DOI: 10.1007/BF00205736.


Ly 1+2- suppressor T cells down-regulate the generation of Ly 1-2+ effector T cells during progressive growth of the P815 mastocytoma.

NORTH R, Dye E Immunology. 1985; 54(1):47-56.

PMID: 3156088 PMC: 1454849.


Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell-mediated immunity.

Awwad M, NORTH R J Exp Med. 1988; 168(6):2193-206.

PMID: 2974065 PMC: 2189164. DOI: 10.1084/jem.168.6.2193.